Indian Regulatory Committee Requests Protocol Revisions for Enzene's Nivolumab Biosimilar Phase III Trial
Key Insights
India's Subject Expert Committee (SEC) has directed Enzene Biosciences (search) to revise its Phase III trial protocol for a nivolumab biosimilar targeting head and neck cancer patients.
The committee recommended key modifications including narrowing the non-inferiority margin, adequately powering the pharmacokinetic study, and extending long-term efficacy evaluation to at least 24 weeks.
The proposed trial aims to compare Enzene's biosimilar with the innovator nivolumab (Opdivo®) in adults with recurrent or metastatic squamous cell carcinoma of the head and neck (search) progressing after platinum-based therapy.
India's Subject Expert Committee (SEC) has instructed Enzene Biosciences (search) to revise its Phase III clinical trial protocol for a nivolumab biosimilar before proceeding with the study in patients with head and neck cancer. The regulatory directive reflects heightened scrutiny for biosimilar development in oncology indications.
Trial Design and Patient Population
Enzene Biosciences (search) had sought permission to conduct a prospective, multicenter, randomized, double-blind, parallel-group Phase III trial comparing its biosimilar nivolumab with the innovator product. The study targets adults with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (search) (SCCHN) who are progressing on or after platinum-based therapy. The study was proposed under Protocol No. ALK43/ENZ132-NIVO1, Version 1.0, dated February 14, 2025.
Regulatory Recommendations
After detailed deliberation, the committee recommended several key modifications to the proposed protocol. The SEC advised that the disease control rate (DCR) should be assessed at 12 weeks and that the non-inferiority margin used for sample size calculation should be narrowed. The pharmacokinetic (PK) study must be adequately powered to ensure robust comparative data.
Additionally, the SEC directed that long-term efficacy endpoints should be evaluated for at least 24 weeks, extending beyond the initially proposed timeframe. The protocol must also include provisions for reporting safety data from the initial 20 percent of enrolled subjects, ensuring early detection of any safety signals.
About Nivolumab and Market Context
Nivolumab, a human monoclonal antibody targeting the programmed death-1 (PD-1 (search)) receptor, is a leading immune checkpoint inhibitor that works by enhancing the body's immune response against cancer cells. Marketed globally under the brand name Opdivo®, it is approved for multiple cancers including non-small cell lung cancer (search) (NSCLC), melanoma (search), renal cell carcinoma (search), and head and neck cancers.
Company Background
Enzene Biosciences (search) Ltd, a subsidiary of Alkem Laboratories, is a biotechnology company focused on developing and manufacturing complex biosimilars and novel biologics. The company has been instructed to submit a revised clinical trial protocol incorporating the SEC's recommended changes for further evaluation by the committee before initiating the study.
The SEC's directive reflects its emphasis on ensuring scientific rigor, adequate power, and comprehensive safety assessment in biosimilar development for oncology indications. This regulatory approach underscores the importance of maintaining high standards for biosimilar approval, particularly in cancer therapeutics where patient outcomes are critical.